RBM5 and acute myeloid leukemia: The meta-analysis results (Figure 3) showed that AML patients with aberrant lncRNA expression (high expression of XIST, HOXA-AS2, CRNDE, MALAT-1, ANRIL, SNHG14, ZEB2-AS1, HOTAIR, PANDAR, TUG1, SNHG5, RBM5-AS1, NEAT1, KCNQ1OT1, UCA1, CRNDE, NORAD, etc., and low expression of MEG3, IRAIN) had a shorter OS, indicating a poor prognosis.